CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 47 enrolled
Drug / intervention
ChAdOx1-HBVbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04297917
NCT04297917Phase 1Completed
CompareCT.gov

A Phase 1 Monotherapy Study to Evaluate the Safety, Tolerability & Immunogenicity of Vaccination With Candidate Chimpanzee Adenovirus-vectored HepB Virus Vaccine ChAdOx1 HBV in Healthy Participants & Participants With Chronic HepB Infection

Barinthus Biotherapeutics·interventional·Posted Mar 6, 2020·Updated Aug 12, 2025

In Brief

A Phase 1 clinical trial evaluating ChAdOx1-HBV for Hepatitis B and Healthy. Completed, enrolled 47 participants across 4 sites.

Detailed Summary

This is a Phase 1, first in human study of ChAdOx1-HBV. The study will be conducted in 40 healthy participants and 12 participants with CHB and virally suppressed with oral antiviral medication. This will be an open-label, non randomised dose escalation study comparing the safety, tolerability and immunogenicity of 2 different doses of ChAdOx1 HBV vaccine. T cell responses in healthy participants who have received a prior two-dose series of AZD1222 will be compared with those who have received either the Pfizer COVID 19 vaccine or the Moderna mRNA COVID 19 vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Healthy
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedMar 6, 2020
Enrollment StartFeb 10, 2019
Primary CompletionMay 23, 2022
Study CompletionJun 26, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.3 years ago

Interventions

ChAdOx1-HBVbiological

chimpanzee adenovirus-vectored hepatitis B virus vaccine